UA79583C2 - Use of combined 5-ht1a agonists and serotonin reuptake inhibitors - Google Patents
Use of combined 5-ht1a agonists and serotonin reuptake inhibitors Download PDFInfo
- Publication number
- UA79583C2 UA79583C2 UA2003065408A UA2003065408A UA79583C2 UA 79583 C2 UA79583 C2 UA 79583C2 UA 2003065408 A UA2003065408 A UA 2003065408A UA 2003065408 A UA2003065408 A UA 2003065408A UA 79583 C2 UA79583 C2 UA 79583C2
- Authority
- UA
- Ukraine
- Prior art keywords
- butyl
- physiologically acceptable
- acceptable salt
- piperazine
- benzofuran
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title description 6
- 239000003772 serotonin uptake inhibitor Substances 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 78
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 229940076279 serotonin Drugs 0.000 claims abstract description 13
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 12
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000000018 receptor agonist Substances 0.000 claims abstract description 10
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 10
- 241000282472 Canis lupus familiaris Species 0.000 claims description 13
- 241000282326 Felis catus Species 0.000 claims description 10
- 201000004384 Alopecia Diseases 0.000 claims description 9
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- 241000283086 Equidae Species 0.000 claims description 8
- 230000001107 psychogenic effect Effects 0.000 claims description 8
- 231100000360 alopecia Toxicity 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 3
- 230000035929 gnawing Effects 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 abstract description 19
- 230000000472 traumatic effect Effects 0.000 abstract description 10
- BPSWBRVXRVOQSP-UHFFFAOYSA-N 3-[4-[4-(4-cyanophenyl)piperazin-1-yl]butyl]-1h-indole-5-carbonitrile Chemical compound C1=CC(C#N)=CC=C1N1CCN(CCCCC=2C3=CC(=CC=C3NC=2)C#N)CC1 BPSWBRVXRVOQSP-UHFFFAOYSA-N 0.000 abstract 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 208000035475 disorder Diseases 0.000 description 40
- 241001465754 Metazoa Species 0.000 description 14
- 241000271566 Aves Species 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000003746 feather Anatomy 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- -1 4-(4-cyanophenyl)-piperazin-1-yl Chemical group 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 241000721578 Melopsittacus Species 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 241000287531 Psittacidae Species 0.000 description 2
- 241000287530 Psittaciformes Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 230000002358 autolytic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002089 crippling effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 208000002271 trichotillomania Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 241000388002 Agonus cataphractus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001494208 Neophema Species 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010057342 Onychophagia Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010031253 Osteomyelitis acute Diseases 0.000 description 1
- 206010031256 Osteomyelitis chronic Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00124815 | 2000-11-14 | ||
PCT/EP2001/011952 WO2002040024A1 (fr) | 2000-11-14 | 2001-10-16 | Utilisations nouvelles d'agonistes 5-ht1a et d'inhibiteurs de recaptage de serotinine combines |
Publications (1)
Publication Number | Publication Date |
---|---|
UA79583C2 true UA79583C2 (en) | 2007-07-10 |
Family
ID=8170369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2003065408A UA79583C2 (en) | 2000-11-14 | 2001-10-16 | Use of combined 5-ht1a agonists and serotonin reuptake inhibitors |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040082594A1 (fr) |
EP (1) | EP1333832B1 (fr) |
JP (1) | JP2004513924A (fr) |
KR (1) | KR20030059244A (fr) |
CN (1) | CN1222291C (fr) |
AR (1) | AR031335A1 (fr) |
AU (2) | AU1502702A (fr) |
BR (1) | BR0115296A (fr) |
CA (1) | CA2428511C (fr) |
CZ (1) | CZ302484B6 (fr) |
DE (1) | DE60131675T2 (fr) |
ES (1) | ES2296820T3 (fr) |
HK (1) | HK1060697A1 (fr) |
HU (1) | HUP0302751A3 (fr) |
MX (1) | MXPA03004166A (fr) |
NO (1) | NO20032148L (fr) |
PL (1) | PL204331B1 (fr) |
RU (1) | RU2288719C2 (fr) |
SK (1) | SK287337B6 (fr) |
UA (1) | UA79583C2 (fr) |
WO (1) | WO2002040024A1 (fr) |
ZA (1) | ZA200304606B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10305739A1 (de) * | 2003-02-11 | 2004-08-19 | Merck Patent Gmbh | Benzofuranderivate |
BRPI0417858B1 (pt) * | 2003-12-23 | 2017-10-10 | H. Lundbeck A/S | Derivative compounds of aniline and pharmaceutical composition that understand it |
US7893261B2 (en) | 2004-03-26 | 2011-02-22 | Baylor University | Serotonin reuptake inhibitors |
AR052308A1 (es) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
WO2006034788A1 (fr) * | 2004-09-28 | 2006-04-06 | Merck Patent Gmbh | Combinaisons de derives de n-(indolecarbonyl-)piperazine et d'inhibiteurs de la recapture de la serotonine |
AR054393A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
US20100184852A1 (en) * | 2006-08-11 | 2010-07-22 | Antoine De Saizieu | Organic compounds for treatment of disorders connected to impaired neurotransmission |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4333254A1 (de) * | 1993-09-30 | 1995-04-06 | Merck Patent Gmbh | Piperidine und Piperazine |
DE19512639A1 (de) * | 1995-04-05 | 1996-10-10 | Merck Patent Gmbh | Benzonitrile und -fluoride |
DE19637237A1 (de) * | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
DE19730989A1 (de) * | 1997-07-18 | 1999-01-21 | Merck Patent Gmbh | Piperazin-Derivate |
BR9912299A (pt) * | 1998-07-20 | 2001-11-20 | Merck Patent Gmbh | Derivados de bifenila |
-
2001
- 2001-10-16 WO PCT/EP2001/011952 patent/WO2002040024A1/fr active IP Right Grant
- 2001-10-16 CA CA002428511A patent/CA2428511C/fr not_active Expired - Fee Related
- 2001-10-16 UA UA2003065408A patent/UA79583C2/uk unknown
- 2001-10-16 DE DE60131675T patent/DE60131675T2/de not_active Expired - Lifetime
- 2001-10-16 AU AU1502702A patent/AU1502702A/xx active Pending
- 2001-10-16 EP EP01983555A patent/EP1333832B1/fr not_active Expired - Lifetime
- 2001-10-16 HU HU0302751A patent/HUP0302751A3/hu unknown
- 2001-10-16 SK SK638-2003A patent/SK287337B6/sk not_active IP Right Cessation
- 2001-10-16 US US10/416,573 patent/US20040082594A1/en not_active Abandoned
- 2001-10-16 PL PL360310A patent/PL204331B1/pl not_active IP Right Cessation
- 2001-10-16 ES ES01983555T patent/ES2296820T3/es not_active Expired - Lifetime
- 2001-10-16 RU RU2003115431/15A patent/RU2288719C2/ru not_active IP Right Cessation
- 2001-10-16 KR KR10-2003-7006473A patent/KR20030059244A/ko not_active Application Discontinuation
- 2001-10-16 CZ CZ20031433A patent/CZ302484B6/cs not_active IP Right Cessation
- 2001-10-16 CN CNB018188591A patent/CN1222291C/zh not_active Expired - Fee Related
- 2001-10-16 BR BR0115296-3A patent/BR0115296A/pt not_active Application Discontinuation
- 2001-10-16 AU AU2002215027A patent/AU2002215027B2/en not_active Ceased
- 2001-10-16 MX MXPA03004166A patent/MXPA03004166A/es active IP Right Grant
- 2001-10-16 JP JP2002542397A patent/JP2004513924A/ja active Pending
- 2001-11-14 AR ARP010105299A patent/AR031335A1/es unknown
-
2003
- 2003-05-13 NO NO20032148A patent/NO20032148L/no not_active Application Discontinuation
- 2003-06-12 ZA ZA200304606A patent/ZA200304606B/en unknown
-
2004
- 2004-05-25 HK HK04103692A patent/HK1060697A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SK6382003A3 (en) | 2003-11-04 |
CN1222291C (zh) | 2005-10-12 |
HUP0302751A3 (en) | 2007-06-28 |
CN1474691A (zh) | 2004-02-11 |
PL360310A1 (en) | 2004-09-06 |
MXPA03004166A (es) | 2003-09-22 |
CZ20031433A3 (cs) | 2003-09-17 |
SK287337B6 (sk) | 2010-07-07 |
AU2002215027B2 (en) | 2006-10-05 |
CA2428511C (fr) | 2009-12-29 |
CA2428511A1 (fr) | 2002-05-23 |
KR20030059244A (ko) | 2003-07-07 |
PL204331B1 (pl) | 2010-01-29 |
CZ302484B6 (cs) | 2011-06-08 |
US20040082594A1 (en) | 2004-04-29 |
JP2004513924A (ja) | 2004-05-13 |
EP1333832A1 (fr) | 2003-08-13 |
BR0115296A (pt) | 2003-09-02 |
EP1333832B1 (fr) | 2007-11-28 |
NO20032148D0 (no) | 2003-05-13 |
NO20032148L (no) | 2003-05-13 |
DE60131675T2 (de) | 2008-11-20 |
RU2288719C2 (ru) | 2006-12-10 |
DE60131675D1 (de) | 2008-01-10 |
HK1060697A1 (en) | 2004-08-20 |
ZA200304606B (en) | 2004-09-13 |
HUP0302751A2 (hu) | 2003-11-28 |
WO2002040024A1 (fr) | 2002-05-23 |
AU1502702A (en) | 2002-05-27 |
AR031335A1 (es) | 2003-09-17 |
ES2296820T3 (es) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11785950B2 (en) | Use of dried chicory root to protect poultry and livestock against ectoparasites or as insect repellant | |
UA79583C2 (en) | Use of combined 5-ht1a agonists and serotonin reuptake inhibitors | |
AU2002215027A1 (en) | Novel uses of combined 5-HT1A agonists and serotonin reuptake inhibitors | |
Wickens et al. | 37 Stereotypic and Behavior Disorders | |
RU2283648C2 (ru) | Новое применение комбинированных селективных антагонистов допаминового рецептора d2 и агонистов рецептора 5-нт 1a | |
Anderson et al. | Prevention of lameness in cow-calf operations | |
ES2949316T3 (es) | Uso oral de gluconatos de zinc y cobre en el tratamiento de la dermatitis digital | |
Sorathiya | Association of Good Dairy Farming Practices, Welfare and Performance: A Review | |
Theobald | Experiences in maintaining an exotic cat collection at the Cincinnati Zoo | |
Whiteker et al. | Pork Industry Handbook Feed Additives for Swine (Revised 1978) | |
Gholve et al. | Comparative efficacy of commonly used anthelmintics against toxocarosis in buffalo calves in Mumbai, Maharashtra | |
FR2619310A1 (fr) | Compositions zootechniques renfermant du salbutamol | |
UA22042U (en) | Method for stimulating sexual function and improving reproductive quality in sows |